Elekta is a company within the Medical Technology category. Elekta is a global leader in precision radiation medicine, developing and delivering innovative solutions for cancer treatment, including adaptive radiotherapy systems, integrated imaging, planning, and treatment workflows. Their technology aims to provide more precise and personalized care for various cancer types.
Elekta was founded in 1972 and is headquartered in Stockholm, Sweden.
Elekta is rated Emerging on the Optimly Brand Authority Index, a measure of how well AI models can accurately describe the brand. The exact score is locked for unclaimed profiles.
AI narrative accuracy for Elekta is Strong.
AI models classify Elekta as a Incumbent. AI names brand first.
Elekta appeared in 5 of 5 sampled buyer-intent queries (100%). The brand is highly discoverable for its core offerings, adaptive radiotherapy and cancer treatment, as well as specific product mentions and cancer types. No significant discoverability gaps are evident in the provided context.
Elekta is strongly positioned as a pioneering and leading provider of adaptive radiotherapy solutions, committed to advancing cancer care through precision, personalized treatment, and integrated workflows. The brand emphasizes its long-standing expertise and the clinical benefits of its technology. Key gap: No significant discrepancies were identified between different claims or sources within the provided text.
Of 4 key facts verified about Elekta, 4 are well-documented (likely accurate across AI models), 0 have limited sourcing, and 0 are retrieval-dependent and may be inaccurate without live search.
The provided text does not explicitly present any vulnerabilities for Elekta. Potential challenges might involve the complexity of implementing advanced adaptive radiotherapy systems or the associated costs for healthcare providers.
Buyers turn to Elekta for Manual Radiotherapy Planning: Traditional methods of radiotherapy planning that require extensive manual intervention for contouring, dose calculation, and adjustment, lacking real-time adaptation and, Oncology Consulting & Planning Services: External consulting firms specializing in optimizing cancer treatment protocols and clinic workflows without providing proprietary technology or adaptive treat, Continue with non-adaptive treatment: Proceeding with existing, less flexible radiotherapy methods that do not account for daily anatomical changes, potentially leading to sub-optimal targeting, incre, among 3 documented problem areas.
Buyers evaluating Elekta typically ask AI models about "Elekta adaptive radiotherapy", "Elekta cancer treatment solutions", "radiotherapy for prostate cancer", and 3 similar queries.
Elekta's core products are Adaptive radiotherapy systems (MR-guided and CT-guided workflows), adaptive radiosurgery, brachytherapy, Leksell Gamma Knife..
Elekta uses Enterprise-level sales, capital equipment sales, maintenance contracts, and possibly software licenses..
Elekta serves Hospitals, cancer centers, oncology clinics, medical professionals involved in radiation therapy..
Elekta Over 50 years of experience, focus on adaptive radiotherapy as a new standard of care, integrated precision in imaging, planning, and treatment, and a wide range of indications treated.
Brand Authority Index (BAI) tier: Emerging (exact score locked for unclaimed brands)
Archetype: Incumbent
https://optimly.ai/brand/elekta
Last analyzed: August 9, 2026
Founded: 1972
Headquarters: Stockholm, Sweden
This profile is part of the Optimly Brand Trust Registry — a verified index of 60,000+ brand profiles that AI models read from when answering buyer-intent questions about brands and categories. Optimly identifies which third-party sources AI cites about each brand, prepares structured brand information for those sources, and measures whether AI representation improves.
If this is your brand, you can claim this profile to verify its contents and correct what AI models say about you: Claim this profile